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Abstract
Introduction: This study intends to show that the current widely used computer-aided detection (CAD) may
be helpful, but it is not an adequate replacement for the human input required to interpret mammograms
accurately. However, this is not to discredit CAD’s ability but to further encourage the adoption of artificial
intelligence-based algorithms into the toolset of radiologists.
Methods: This study will use Hologic (Marlborough, MA, USA) and General Electric (Boston, MA, USA) CAD
read images provided by patients found to be Breast Imaging Reporting and Data System (BI-RADS) 6 from
2019 to 2020. In addition, patient information will be pulled from our institution’s emergency medical record
to confirm the findings seen in the pathologist report and the radiology read.
Results: Data from a total of 24 female breast cancer patients from January 31st 2019 to April 31st 2020, was
gathered from our institution’s emergency medical record with restrictions in patient numbers due to
coronavirus disease 2019 (COVID-19). Within our patient population, CAD imaging was shown to be
statistically significant in misidentifying breast cancer, while radiologist interpretation still proves to be the
most effective tool.
Conclusion: Despite a low sample size due to COVID-19, this study found that CAD did have significant
difficulty in differentiating benign vs. malignant lesions. CAD should not be ignored, but it is not specific
enough. Although CAD often marks cancer, it also marks several areas that are not cancer. CAD is currently
best used as an additional tool for the radiologist.
Categories: Radiology, Oncology, Epidemiology/Public Health
Keywords: artificial intelligence, machine learning, breast, cancer, mammogram
Introduction
As society becomes more advanced, so does the technology that accompanies it; as software and the field of
artificial intelligence and machine learning begin to evolve, so must society. The most significant point
against automation’s progress is the idea that it can replace the complex human role in the process [1,2]. In
the field of diagnostic radiology there is a common distrust in Computer-Aided Detection (CAD) with the
underlying reasons ranging anywhere from it being a somewhat recent addition to the field in the early
2000s to CAD’s seemingly inability to consistently provide a benefit to the radiologist [3,4]. This study
intends to illustrate that current CAD is not an adequate replacement for the human input required to
interpret mammograms accurately. This study intends to decrease the current anxiety that both current and
future radiologists may have regarding the field’s security. Among women in the United States, breast
cancer remains the second most diagnosed type of cancer after skin cancer, with this statistic holding when
extrapolated to the worldwide population [5-8]. As such, one cannot neglect the importance of early
detection through routine mammography screening, and the early detection of breast cancer is associated
with better outcomes [5,6]. However, with each mammogram taken, there must be a radiologist that not
only reads it but does so with both high accuracy and at a high volume. CAD-based mammography systems
have seen extensive use in the United States following their introduction in 2001; however, since its
introduction, CAD has received mixed approval from radiologists regarding its performance [3,4]. One of the
more common thoughts is that CAD itself may adversely affect radiologist performance and increase the
number of unnecessary biopsies while providing no significant improvement in cancer detection rates [3-9].
However, while CAD has seen noticeable improvements in accuracy, it could be argued that it remains in its
infancy 20 years after its introduction. With that in mind, should CAD be partnered with a radiologist to
emulate a double read, the overall theoretical cost could remain low [1,10,11]. This would allow an increase
in volume to be adopted by the overseeing radiologist [1,10,11]. If efficiently implemented into the
healthcare system, this increase in volume could accelerate the decrease in breast cancer mortality by
expanding access to high‐quality preventive care at a fraction of the cost [5,6,8,12,13].
Materials And Methods
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During the extent of this study, patient information and data on the diagnosis was gathered post patient
visit. Inclusion criteria for patient eligibility were that the patient had to be over the age of 18 and had
received either craniocaudal (CC) or mediolateral oblique (MLO) mammography during their visit. The
patient must have been categorized under Breast Imaging, Reporting & Data System (BI-RADS) as category
6, biopsy-proven malignancy, between January 1st, 2019, and December 31st, 2020. Patient's data was not
eligible for analysis in the study if they lacked proper mammogram/breast imaging, if there was an inability
to access CAD data for the patient’s imaging, or if they received a pathology report negative for breast cancer
(a negative report being classified as BI-RADS category 1 or 2). If the patient met all inclusion criteria and
none of the exclusion criteria, their first name, last name, and medical records number (MRN) were recorded
within a master data sheet for safekeeping. University of Texas Medical Branch Institutional Review Board
issued approval IRB #20-0018.
The number of patients included in the study depended mainly on the volume seen between January 1st,
2019 and December 31st, 2020; however, a sample size between 50 and 100 was predicted based on past
trends. Due to the time-limited storage of the CAD data within the institution’s system, only the most recent
CAD reads were used throughout this study. Mammogram imaging and CAD reads were obtained and viewed
via the Hologic “SecurView® DX” workstation (Hologic, Marlborough, MA, USA) and the included
proprietary software. Because of limitations to the CAD data storage, the CAD annotated images of the most
recent CAD reads were exported to a password-encrypted disk drive that remained locked within the
institution's Department of Radiology. Images were used to record CAD data and were deidentified and
disposed of upon completion of the study. Once the CAD reads had been saved, a tally of all CAD markers
was recorded onto a master datasheet.
Variables that were recorded onto the master datasheet include patient’s name, MRN, patient identifier
code, CAD software used (Hologic or General Electric [Boston, MA, USA]), left and right CC CAD marks, left
and right MLO view CAD marks, what was detected in CC CAD, what was detected in MLO CAD, breast
density (almost entirely fat, scattered fibroglandular, heterogeneously dense, and extremely dense),
radiologic findings of biopsy-proven cancer (mass, calcification, or asymmetry), and the cancer type by
pathology report. Each CC and MLO view had their CAD data in terms of the amount of “CAD markings”
recorded. The columns “Cancer CC Detected” and “Cancer MLO Detected” were both be used to determine
whether or not the left and right breast were found to have one of the five findings, Cancer Hit, Cancer
Missed, Cancer Missed w/ Benign Findings, Benign Findings, or No Findings. The two instances of CAD used
at the institution included the Hologic and General Electronic’s iteration of the CAD algorithm. The Hologic
CAD software markings asterisk, triangle, and cross represent masses, calcification clusters, and a
combination mass + calcifications cluster, respectively. Additionally, the General Electric CAD software
marked a circle and square representing a mass and calcifications cluster, respectively. Breast density and
the final pathology report findings were extracted from the institution’s Epic EMR. Once data gathering has
concluded, all variables recorded aside from the patient name and MRN were transferred to a separate data
analysis datasheet for statistical analysis. A unique study identifier was used in the data analysis datasheet
to help ensure patient privacy and confidentiality.
Results
Data from 24 female breast cancer patients from January 31st, 2019 to April 31st, 2020, was gathered from
the institution's Epic emergency medical record. While the original protocol called for this study to continue
for the entire 2020 year, it was decided to end the study prematurely due to the COVID-19 pandemic that
began in the spring of 2020.
Of the 24 patients who met inclusion criteria and underwent CAD imaging, radiologists were able to detect
all cancer, and CAD was able to detect most of the cancer. CAD missed the detection of cancer in one of the
two views (CC and MLO) for three patients. These data are shown in Table 1, including pathology findings
and markings depicted from CAD for each of the patients. The type of breast density also plays a big part in
CAD readings. It was found that CAD tends to have a hard time differentiating between malignant or benign
in dense breast tissue. In dense breasts (heterogeneously dense or extremely dense), it was found that CAD
had an average total marking of 5.33 compared to the fatty breast (fatty and scattered fibroglandular
densities) of 4.73, shown in Table 2. An example of dense breasts is shown in Figure 1, and an example of
fatty breasts is shown in Figure 2.








# of CAD calcification markings in breast with
cancer
# of CAD mass markings in breast with
cancer
Total number of CAD
markings
1 Yes  Yes2 #1 IDC M 0 1 1
2 Yes Yes #1 IDC, DCIS M 5 3 8
3 Yes Yes #1 IDC, DCIS M 4 8 12
4 Yes Yes #1 DCIS C 0 3 3
5 Yes Yes #1 IDC, DCIS C 3 3 6
61 Yes Yes
Left: #1 DCIS Right: #2
DCIS
Left: M Right: M 5 4 9
7 Yes Yes #1 IDC, DCIS C 0 3 3
8 Yes Yes #1 IDC M 0 2 2
9 Yes Yes #1 IDC M 1 3 4
10 Yes Yes #1 DCIS C 1 2 3
11 Yes Yes #1 IDC A 2 3 5
12 Yes Yes #1 IDC M 5 2 7
13 Yes Yes #1 IDC #2 IDC M 3 1 4
14 Yes Yes #1 IDC, DCIS M 0 4 4
15 Yes Yes #1 IDC M 5 2 7
16 Yes  Yes2 #1 IDC, DCIS M 0 1 1
17 Yes Yes #1 IDC MC 2 4 6
18 Yes Yes #1 IDC #2 IDC, DCIS MC 4 5 9
19 Yes Yes #1 IDC M 0 2 2
20 Yes Yes #1 IDC M 0 3 3
21 Yes Yes #1 IDC MC 0 4 4
22 Yes  Yes2 #1 IDC #2 IDC M 1 3 4
23 Yes Yes #1 DCIS #2 IDC M 2 2 4
 241 Yes Yes






TABLE 1: CAD able to detect calcifications and masses, but unable to distinguish the malignant
from benign.
1Patient has bilateral breast cancer
2CAD missed detection in one of the two views (CC or MLO)
#1-First biopsy, #2-Second biopsy
Computer-aided detection (CAD), Invasive Ductal Carcinoma (IDC), Ductal Carcinoma in Situ (DCIS), Mass (M), Calcifications (C), Asymmetry (A),
Mass with Calcifications (MC)
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Patient with dense breasts Number of CAD calcification markings in breast with cancer Number of CAD mass markings in breast with cancer Total number of CAD markings
1 0 1 1
2 5 3 8
3 4 8 12
4 0 3 3
5 3 3 6
 61 5 4 9
7 0 3 3
8 0 2 2
9 1 3 4
Average number of markings in dense breast 2 3.3 5.3
Patient with fatty breasts Number of CAD calcification markings in breast with cancer Number of CAD mass markings in breast with cancer Total number of CAD markings
10 1 2 3
11 2 3 5
12 5 2 7
13 3 1 4
14 0 4 4
15 5 2 7
16 0 1 1
17 2 4 6
18 4 5 9
19 0 2 2
20 0 3 3
21 0 4 4
22 1 3 4
23 2 2 4
 241 5 3 8
Average number of markings in fatty breast 2 2.7 4.7
 
TABLE 2: Computer-aided detection (CAD) marks less findings in fatty breasts (fatty and
scattered fibroglandular densities) than dense breasts (heterogeneously dense and extremely
dense breasts). This means CAD has a harder time and overcalls more in dense breasts.
1Patient has bilateral breast cancer
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FIGURE 1: Hologic Computer-aided detection (CAD)* in Dense Breast
Patient with Biopsy-Proven Cancer (red circle denotes location of
cancer).
(a) Right Breast craniocaudal (CC) view without CAD; (b) Right Breast mediolateral oblique (MLO) view
without CAD; (c) Right Breast CC view with CAD; (d) Right Breast MLO view with CAD.
*Hologic CAD Software Legend: Mass denoted by a black asterisk, calcification clusters denoted by a black
triangle, and combinations of mass + calcification clusters are denoted by a black cross.
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FIGURE 2: Hologic Computer-Aided Detection (CAD)* in Fatty Breast
Patient with Biopsy-Proven Cancer (red circles denote location of
cancers)
(a) Left Breast craniocaudal (CC) view without CAD; (b) Left Breast mediolateral oblique (MLO) view without
CAD; (c) Left Breast CC view with CAD; (d) Left Breast MLO view with CAD.
*Hologic CAD Software Legend: Mass denoted by a black asterisk, calcification clusters denoted by a black
triangle, and combinations of mass + calcification clusters are denoted by a black cross
Analysis of each imaging view (Right CC, Left CC, Right MLO, Left MLO) was conducted to obtain probability
values. Probability values were determined from each specific imaging view from the combined
interpretation from both radiology and pathology readings. Data were analyzed through the use of Fisher’s
exact test. Fisher’s exact test revealed p=0.0417 for right CC CAD interpretation, p=1 for left CC
interpretation, p=0.0417 for right MLO CAD interpretation, and p=0.0345 for left CAD interpretation. The
probability value for the overall CAD interpretation was conducted using the Chi-square test. It was
determined from both the combined interpretation from both radiology and pathology readings for all the
views. All values revealed a significant correlation except the left CC CAD interpretation. Despite the small
sample size, results showed to be significant in the regard that CAD still needs a human operator to detect
cancer.
Discussion
Artificial intelligence-based algorithms that incorporate machine learning and deep learning are drawing a
lot of interest amongst radiologists and the public. However, at this point, those algorithms are not currently
widely adopted by breast imaging centers across the nation. The current widely used CAD technology is still
too unrefined at the moment. Artificial intelligence-based algorithms improving upon the current CAD
would require further research in addition to further investigations into how its implementation in a clinical
setting affects patient care. McKinney et al. support this by noting that clinical trials are needed for AI;
however, they believe that AI has a role in the future in aiding early detection of breast cancer once refined
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[1,7,14,15]. McKinney et al.’s [15] study illustrated that CAD is capable of excellent results in controlled
testing, but the opposite may occur in real-world scenarios due to various factors including, but not limited
to, the radiologists ignoring or misusing CAD due to the high frequency of marks detected that showed no
signs of cancer [3,4,7,14] which result in a large number of callbacks [7,14].
Regarding CAD’s effect on radiologist’s reads, Du-Crow et al. [1] showed that observer sensitivity was
significantly greater for markers detected by CAD compared to the same markers without CAD (t51=6.56,
p<0.001); with no significant difference between no-CAD and CAD conditions on markers that were not
detected by CAD. This shows that CAD itself may play a significant role in augmenting the radiologist’s
ability as a tool. The data shows that while CAD’s algorithm can detect a potential instance of breast cancer,
CAD is not currently able to differentiate between benign and malignant cases of breast cancer. Due to this
lack of differentiation, CAD detects many benign findings that untrained eye could be falsely reported as
cancer requiring further workup. In working up these cases, unnecessary harm and financial burden may be
placed upon the patient through an increase in unnecessary biopsies, and all the additional imaging and
procedural cost needed to confirm the findings are non-cancerous [9]. Winch et al. [9] concluded that false
positives leading to unnecessary biopsy and further testing could cause patients to worry and develop a fear
of cancer until the results are returned and discussed. In addition to this, the legal implication and the
liability holder of having a CAD-only system in a hospital is a topic that has not been discussed and would
not have a clear-cut answer in the policy.
Overall, due to the relative infancy of CAD, the diversity of the real-world setting, in addition to the
program’s inexperience with these demographics, has allowed conflicting information regarding the
accuracy of CAD to be published. For example, Lehman et al. [3,4] demonstrate that there was no
improvement in the diagnostic accuracy of CAD from a sample of extensive data from the US Breast Cancer
Surveillance Consortium registry of clinical mammography interpretations. However, another study on
digital breast tomosynthesis CAD system found that detected a good amount of breast cancers that
presented via masses or microcalcification clusters (89%, 99 of 111) with an acceptable false-positive rate.
While it may be impossible to truly understand whether these conflicting views on CAD are caused by
varying patient population or differing technology, further studies are certainly needed to explore the
interactions of radiologists and CAD systems [16].
Conclusions
Technology will continue to advance, and artificial intelligence will improve. However, machines replacing
humans is unlikely because studies similar to this one will likely continue to show that human plus machine
is greater than machine alone. Thus, it is more likely that the technology will add a tool aiding radiologist
interpretation rather than replace the radiologist.
Study limitations include factors such as our sample size, which may decrease the significance and
generalizability of our results, limitations in the number of CAD data retrieved, differences in detection
algorithms between different CAD databases, and the potential decrease of generalizability due to
differences in the patient population. Of note, this study had to end prematurely due to the impact of
COVID-19 on elective procedures during the Spring, Summer, and Fall of 2020. This limited the number of
our patients in the study, which could have provided more support to the significant findings we found with
our 24 patients. It may be challenging to be able to compare the various CAD systems used by most
institutions accurately; however, it may be possible to alleviate the study limitations of sample size, patient
generalizability, and CAD generalizability by creating a multi-institution partnership designed around
comparing the CAD systems across the varying institutions. A study on this scale may be difficult to organize
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